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The a isoform of Topoisomerase IIa (Topo IIa) is a proliferation marker as well as a target for several chemotherapeutic agents such
as anthracyclines. In vitro studies have demonstrated the relationship between the Topo IIa expression level and chemosensitivity of
target cancer cells. To verify this effect in vivo, we selected 125 patients presenting with T243cm and T3 N0–1M0 breast tumours
who were treated by six cycles of primary chemotherapy, including epirubicin before any surgery. Therapy response was assessed by
clinical and X-ray mammogram measurements of tumour shrinkage. The pretherapeutic core biopsies were immunostained with a
monoclonal antibody (Ki-S7) against Topo IIa. Ki-S7 positivity ranged from 0 to 50% (median, 15%). A high percentage of Ki-S7-
positive cells (415%) was associated with tumour regression under chemotherapy (OR¼2.88, CI: 1.3–6.4, P¼0.004). Ki-S7 further
emerged as an independent predictor of tumour regression (OR¼3.34, CI: 1.41–7.93, P¼0.006), together with tumour size of less
than 40mm (OR¼3.82, CI: 1.58–9.25, P¼0.002) and negative oestrogen receptor (ER) status (OR¼3.35, CI: 1.43–7.86,
P¼0.005), in a multivariate analysis including tumour size, SBR grade, ER and PR status, Ki-67, p53 and Her-2/neu. Our clinical results
confirm in vitro data on the relationship between Topo IIa expression and tumour chemosensitivity and thus may have important
practical implications.
British Journal of Cancer (2003) 89, 666–671. doi:10.1038/sj.bjc.6601185 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: Topoisomerase IIa; breast cancer; primary chemotherapy; anthracyclines; Her-2/neu
                                                 
Topoisomerase IIa (Topo IIa) is a vital nuclear DNA-binding
enzyme that controls and modifies the topologic states of DNA
(Berger et al, 1996) by combining nuclease, helicase and ligase
activities. Topo IIa reduces DNA supercoiling and twisting by
creating a double-strand nick that enables the passage of a second
DNA double-strand through the break and subsequent religation
of the cleaved DNA strand. Topo IIa is the specific target of several
chemotherapeutic agents, including anthracyclines. These drugs
bind to Topo IIa–DNA complexes and inhibit the religation step,
which results in stabilisation of the DNA double-strand breaks that
are thought to induce apoptosis (Kellner et al, 2002).
It has been previously demonstrated in vitro that the sensitivity
of tumour cell lines to various Topo IIa poisons, such as
anthracyclines or etoposide, depends on the level of Topo IIa
expression (Gudkov et al, 1993; Asano et al, 1996a, b; Vassetzky
et al, 1996; Withoff et al, 1996a, b; Zhou et al, 1999; Stacey et al,
2000). Moreover, the TOP2a gene being located at 17q12–21 close
to the Her-2/neu oncogene, coamplification of the Her-2/neu and
TOP2a genes was observed in 44% of breast cancers, whereas the
TOP2a was deleted in another 42% (Jarvinen et al, 2000). It also
appears that Topo IIa expression is often correlated to Her-2/neu
overexpression in breast carcinoma. This complex relationship
between the two genes may explain the altered sensitivity to
anthracyclines of Her-2/neu-amplified breast carcinomas (Bitran
et al, 1996; MacGrogan et al, 1996a; Niskanen et al, 1997; Clahsen
et al, 1998; Jarvinen et al, 1998; Paik et al, 1998; Thor et al, 1998;
Vincent-Salomon et al, 2000). Most previous studies regarding the
effect of Topo IIa poisons in relation to the cellular level of Topo
IIa expression were either performed in vitro or on breast tumour
fragments without analysis of the direct in vivo effect (Gudkov et al,
1993; Asano et al, 1996a, b; Vassetzky et al, 1996; Withoff et al,
1996a, b; Zhou et al, 1999; Stacey et al, 2000). The aim of our study
was to analyse this effect in a series of breast carcinoma patients
treated by primary chemotherapy, and to study the relationship
between Topo IIa and Her-2/neu in this setting. To this end, we
investigated the predictive and prognostic values of Topo IIa
expression by immunohistochemical detection of the enzyme in
breast tumour core biopsies from patients with large operable
invasive cancers of the breast treated by primary chemotherapy
including epirubicin. Furthermore, we studied the relationship
between Topo IIa expression and different factors modifying
tumour chemosensitivity, such as Her-2/neu, hormonal receptor,
Ki-67 and p53 immunohistochemical detection.
MATERIALS AND METHODS
Patients
Immunohistochemical detection of Topo IIa was performed on
tumour core biopsies from 128 patients with primary metastasis-
free operable breast cancers, larger than 3cm. These patients Received 2 December 2002; revised 7 May 2003; accepted 5 June 2003
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ybelonged to the neoadjuvant chemotherapy arm of a randomised
phase III trial that compared modified radical mastectomy
followed by adjuvant chemotherapy to neoadjuvant chemotherapy
followed by adapted locoregional treatment in large operable
breast tumours. The clinical trial was conducted at Bergonie ´
Institute from January 1985 to April 1989 and included a total of
272 patients. The chemotherapy regimens used in the trial
comprised three courses of epirubicin, vincristine and methotrex-
ate (EVM) followed by three courses with mitomycin C, thiotepa
and vindesin (MTV), for more details see Mauriac et al (1999). All
the biopsies analysed in the present study came from the primary
chemotherapy, arm of the clinical trial. After completion of the six
courses of chemotherapy, clinical examination and mammography
were used to assess tumour regression. Subsequent locoregional
treatment depended on the extent of tumour regression: radio-
therapy was applied exclusively in case of complete regression,
conservative surgery with axillary node dissection followed by
radiotherapy were performed when tumour regression was
incomplete with residual tumour measuring less than 2cm in
diameter; the remaining patients underwent mastectomy.
The predictive and prognostic value of the immunohistochem-
ical detection of oestrogen and progesterone receptors, p53, Her-2/
neu, and Ki-67 (antibody: Mib-1), had been analysed previously on
the same cohort (MacGrogan et al, 1996a) and served as reference
data for the current study.
Immunohistochemical assay
The pretherapeutic tumour core biopsies fixed in Holland’s fluid
and embedded in paraffin were retrieved from the files of Institute
Bergonie ´. Five mm thick were cut, mounted on silane-coated slides
and routinely processed. Antigen retrieval was obtained by heating
the sections immersed in 0.01 M citrate buffer, pH 6.0, in a pressure
cooker for 20min. The sections were then incubated for 60min
with Ki-S7, a monoclonal antibody specific for Topo IIa. Ki-S7 was
elaborated after immunising Balb/c mice with crude L428 nuclear
extracts, performing mouse splenic/myeloma hybridoma cell
cultures and purifying cell culture supernatants on a G-Sepharose
4 Fast Flow column (Pharmacia LKB; Freiburg, Germany) (Kellner
et al, 1997). Ki-S7 specificity for Topo IIa was verified in
immunoprecipitation and Western blot experiments. Ki-S7 im-
munoreactivity on archival paraffin-embedded tumour material
using an antigen retrieval procedure was also controlled (Kellner
et al, 1997).
Ki-S7 was used undiluted as a lyophilised cell culture super-
natant reconstituted with 5ml H2O. The immunoreaction was
enhanced by means of an avidin–streptavidin–biotin peroxidase
technique (Strept ABC complex/HRP Duet kit, Dako, France) with
diaminobenzidine as a chromogen. MCF7 cell pellets with a high
percentage of cells in G2 phase were fixed in Holland’s fluid and
embedded in paraffin to serve as positive controls in each series
assayed immunohistochemically for Topo IIa expression. Negative
controls consisted of normal nonhyperplastic epithelial cells
present in terminal ductal lobular units in the breast core biopsies.
All slides were read by one of the authors (GMG) who was
blinded to the clinical results. Only unequivocal nuclear staining of
invasive tumour cells was scored as positive (Figure 1). The
percentage of positive tumour cells per tissue section was
determined semiquantitatively in 5% steps.
Statistical analysis
The threshold used for p53 positivity was 1%; for IHC-ER and
IHC-PR positivity, the threshold was 10%. These optimal thresh-
olds have already been determined in previous studies to be the
most informative for clinical outcome (de Mascarel et al, 1995;
MacGrogan et al, 1995; MacGrogan et al, 1996a, b). A Ki-67 (Mib1)
index of 40% was arbitrarily chosen as a threshold, at the
beginning of the study, to differentiate highly proliferating
tumours. This Ki-67 threshold had been chosen in our previous
study on the same group (MacGrogan et al, 1996a), because it
corresponded to the 75th percentile of Ki-67 expression in the
series. Furthermore, 10% of positive invasive cancer cells with a
moderate to strong intensity of staining was chosen for the
Her2neu positivity threshold (Slamon et al, 2001). Finally, the
median values of patients’ ages and tumour sizes were chosen as
cutoff points for the statistical analysis.
The w
2 test was used to investigate the significance of the
relationship between Ki-S7 and the different immunohistochem-
ical factors previously studied as well as the histological Scarff
Bloom and Richardson (SBR) grade. The relation between Ki-S7
and the patient’s age as well as tumour size was analysed by
Student’s t-test. A Kendall t rank correlation test was performed to
study the relationship between Ki-S7 and Ki-67, considering them
as continuous variables.
The clinical size of the tumours was assessed before treatment,
before the second and fourth courses of chemotherapy and after
the sixth. A univariate analysis studying the relationship between
tumour regression and the different factors was performed, using
the w
2 test. Reciprocal influence among the different predictive
factors was determined by multivariate analysis using a logistic
Figure 1 Nuclear immunostaining (Topo IIa) of 25% cells in a Holland’s
bouin-fixed paraffin-embedded microbiopsy of an invasive ductal carcinoma
NOS using monoclonal antibody Ki-S7 specific for topoisomerase IIa (A).
Haematoxylin eosin saffron stain of the same case (B). Scale bar¼50mm.
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yregression test for multiple proportional hazards. The variable to
predict was tumour regression X50%, including complete tumour
regression. To evaluate the predictive impact of Ki-S7 expression
in this series, a first logistic regression model was performed
(model 1), including all previously analysed factors without Ki-S7
(MacGrogan et al, 1996a). A second logistic regression model was
then performed, after adding Ki-S7 (model 2). All factors were
included in the logistic regression analyses, irrespective of their P-
value by univariate analysis; but only those with a P-value p1%
were retained in the final models.
The log-rank test using the Kaplan–Meier method was also used
to study the relationship between KiS-7 and prognosis expressed as
a 5-year probability of survival. Patient follow-up was carried out
quarterly for 2 years, twice a year and finally yearly. For overall
survival (OS), the survival duration was calculated from the
randomisation date to death, or the date they were last known
alive. All causes of death were considered as events. For
metastasis-free interval (MFI) and disease-free interval (DFI), time
to failure was computed from the randomisation date until
metastasis or relapse, or the date they were last known to be
disease-free, respectively. The median follow-up of patients in this
series was 142 months, range 101–172 months.
Univariate and multivariate analyses (logistic regression model)
were performed using version 10.0 of SPSS software.
RESULTS
Invasive carcinoma cells were present in 125 out of 128 biopsies;
three core biopsy paraffin blocks contained no residual tumour
material after tissue sectioning for histological diagnosis and
analysis of the other immunohistochemical factors in the series,
and the corresponding cases were excluded from the analysis.
Patients’ age in this series ranged from 31 to 70 years (mean: 53,
median: 55). The mean and median tumour sizes were 43.2 and
40mm, respectively (range: 20–80mm). The majority of tumours
in this series were invasive ductal carcinomas of no special type
(115, 92.2%), followed by invasive lobular carcinomas (9, 7.2%)
and one mucous carcinoma (0.6%).
Ki-S7 expression in the series
Ki-S7 positivity ranged from 0 to 50% with a median value of 15%
positive tumour cells. 15% was consequently chosen as the threshold
value between low (p 15%) and high (415%) Topo IIa expression.
Relationship between Ki-S7 and other parameters (Table 1)
Ki-S7 was positively associated with SBR grade and p53 expression
(P¼1 10
 6. and 0.03, respectively) and negatively with the
immunoexpression of ER and PR (P¼0.007 and 0.03, respec-
tively). No significant association was found between Ki-S7 and
Her-2/neu or tumour size (Table 1).
Ki-S7 and Ki-67 were strongly positively correlated (t¼0.46,
Po10
 3) and associated (P¼4 10
 7), considering them as
continuous or dichotomous variables, respectively.
Predictive and prognostic values of Ki-S7
High expression of Ki-S7 (415%) was associated with tumour
regression X50% including complete tumour regression after six
courses of chemotherapy (OR¼2.88, CI: 1.3–6.4, P¼0.004) by
univariate analysis (Table 2). The median Ki-S7 value was higher
in the good response group (tumour regression X50% and
complete tumour regression) compared to the poor response
group (tumour regression o50%, tumour stabilisation and
progression), 20 and 15%, respectively. To evaluate the predictive
impact of Ki-S7 in this series, a first stepwise logistic regression
model was performed with all the factors that had been previously
analysed in the series, that is, clinical tumour size, SBR grade, IHC-
ER, IHC-PR, Ki-67, p53 and Her-2/neu (Table 3, model 1). In this
model, clinical tumour size less than 40mm, negative IHC-ER
status and high expression of Ki-67 (440%) were found to be
Table 1 Relationship between Ki-S7 expression and classical and immunohistochemical markers
Univariate model
Variables Total
a No.
b (%) Odd ratios 95% CI
c P
Tumour size
p40mm 69 28 40.6
440mm 55 28 50.9 1.52 0.70–3.31 0.25
Histologic SBR grade
Grade 1 25 4 16.0
Grade 2 71 29 40.8 3.63 1.02–14.01 0.024
Grade 3 29 24 82.8 4.87 2.16–11.01 1 10
 6
P53
0 89 36 40.4
X1% 34 21 61.8 2.38 0.98–5.80 0.034
IHC-ER
o10% 41 26 63.4
X10% 82 31 37.8 0.35 0.15–0.82 0.007
IHC-PR
o10% 50 29 58
X10% 71 27 38 0.44 0.20–0.99 0.03
Her2-neu
d
Negative 102 46 45.1
Positive 20 9 45 1.00 0.34–2.87 0.99
KI-67
p40% 97 33 34
440% 27 24 88.9 15.52 4.01–70.18 4 10
 7
aAll the immunohistochemical analyses for all the markers in the series could not be performed because of the scarcity of
tumour material. The number of missing values per marker other than Ki-S7 does not exceed four.
bNumber of patients
with tumours having 415% KI-S7-positive tumour cells.
c95% CI: 95% confidence intervals.
dHer2-neu positive cases were
those with 10% or more positive tumour cells with a moderate or strong intensity of staining, Her2-neu negative cases were
all the other cases.
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was added (Table 3, model 2), independent predictive factors were
clinical tumour size, IHC-ER and Ki-S7. Ki-67 expression was no
longer considered an independent predictive factor for tumour
regression in this second model (P¼0.092).
Considering the impact of concurrent Topo IIa and Her-2/neu
overexpression on tumour chemosensitivity described in the
literature, the association of these two proteins was analysed in
relation to tumour regression, but no significant correlation was
found either by univariate or multivariate analysis.
By univariate analysis, no statistically significant relationship
was found between Ki-S7 and DFI, MFI or OS (results not shown).
DISCUSSION
Previous studies, showing a relationship between the intracellular
level of Topo IIa and tumour chemosensitivity, were mainly based
on in vitro experiments analysing the efficacy of other Topo IIa
inhibitors in various tumour cell lines, in particular etoposide
(Gudkov et al, 1993; Asano et al, 1996a, b; Vassetzky et al, 1996;
Withoff et al, 1996a, b; Stacey et al, 2000). In the current study, we
have demonstrated for the first time a significant direct in vivo
correlation between the level of Topo IIa expression and breast
cancer response to anthracycline-based chemotherapy. This result
argues in favour of the concept that the efficacy of Topo IIa
Table 2 Factors associated with tumour regression X50%, including complete tumour regression after six
cycles of primary chemotherapy among 125 patients: univariate analysis
Univariate model
Variables (total) Total No.
a OR
b 95% CI
c P
Age (years)
p55 65 32
455 60 23 0.64 0.30–1.39 0.220
Clinical tumour size
440mm 55 17
p40mm 69 37 2.58 1.16–5.83 0.011
Histologic SBR grade
Grade 1 25 9
Grade 2 71 29 1.23 0.43–3.51 0.67
Grade 3 29 17 2.52 0.73–8.85 0.09
ER
X10% 82 26
o10% 41 27 4.15 1.75–9.99 o10
 3
PR
X10% 71 27
o10% 50 25 1.63 0.73–3.63 0.190
Her2-neu
d
Negative 102 41
Positive 20 11 1.82 0.63–5.30 0.221
Ki-67
p40% 97 36
440% 27 18 3.39 1.27–9.21 0.006
Ki-S7
p15% 68 22
415% 57 33 2.88 1.3–6.4 0.004
P53
08 9 3 6
X1% 34 17 1.47 0.62–3.51 0.339
a#:number of patients with tumour regression X50%, including complete tumour regression after six cycles of primary
chemotherapy.
bOR¼odd ratios.
c95CI¼95% confidence interval.
dHer2-neu positive cases were those with 10% or more
positive tumour cells with a moderate or strong intensity of staining, Her2-neu negative cases were all the other cases.
Table 3 Factors associated with tumour regression X50%, including complete tumour regression after six cycles of primary chemotherapy among 125
patients: multivariate analyses (model 1: factors identified in MacGrogan et al, 1996a; model 2: with new factor, Ki-S7)
Model 1 Model 2
B Standard error OR 95 CI P B Standard error OR 95 CI P
Clinical tumour size
440mm Reference Reference
p40mm 1.327 0.451 3.771 1.55–9.12 0.003 1.342 0.450 3.82 1.58–9.25 0.002
IHC-ER
X10% Reference Reference
o10% 1.212 0.436 3.362 1.43–7.9 0.005 1.210 0.435 3.35 1.43–7.86 0.005
Ki-67
p40% Reference Excluded from model 0.092
440% 1.364 0.528 3.910 1.39–10.99 0.010
Ki-S7
p15% – – – – – Reference
415% – – – – – 1.208 0.441 3.347 1.41–7.93 0.006
Each of the odds ratios is adjusted for all other variables in the table. OR¼odd ratio. 95 CI¼95% confidence interval.
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which in turn relates to the cellular expression and activity of Topo
IIa (Kellner et al, 2002).
Jarvinen et al, (1998) found no significant correlation between
Topo IIa expression in primary breast tumours and the regression
of metastases after chemotherapy in patients with advanced breast
cancer treated with first-line epirubicin. The discrepancy between
their results and ours may be attributable to different Topo IIa
contents in primary tumours and their metachronous metastases
Indeed, in a series of 13 breast tumours, the same group
subsequently showed some degree of variability between the Topo
IIa gene status of the primary breast tumour and that of its
metastases by means of fluorescent in situ hybridisation (FISH)
and chromogenic in situ hybridisation (CISH) (Tanner et al, 2001).
Finally it is conceivable that due to intervening acquisition of
drug-resistance mechanisms (Giesler et al, 2002), the effect of
Topo IIa inhibitors may be different in primary tumours and their
corresponding asynchronous metastases, especially if an adjuvant
protocol comprising a Topo IIa inhibitor had previously been
applied.
In line with the proliferation-specific expression of Topo IIa
(Kellner et al, 1997, 2002), we observed a highly significant
correlation between Ki-S7 and Ki-67, which was also reported by
others (Depowski et al, 2000; Rudolph et al, 1999a; Tuccari et al,
1993), in addition to a strong link between the number of Topo
IIa-expressing cells and the S-phase fraction of the cell cycle
(Jarvinen et al, 1996; Sandri et al, 1996a). Given the known
association between high tumour cell proliferation and chemo-
sensitivity (Tannock, 1978; Belembaogo et al, 1992; O’Reilly et al,
1992), one might suspect the observed therapy response to be
related to the proliferative activity of the tumours. Indeed, when
we previously investigated the predictive value of various
immunohistochemical factors in the same cohort (MacGrogan
et al, 1996a), Ki-67 came out as an independent predictive factor
for the therapy response in the multivariate analysis. After
inclusion of Ki-S7 into the logistic regression model, however,
Ki-67 lost its statistical significance. This suggests that Topo IIa
expression may have an impact on the responsiveness of tumours
to cytotoxic therapy beyond its association with tumour cell
proliferation, which is likely related to an increased sensitivity to
the Topo IIa inhibitory component of the treatment protocol, that
is, epirubicin (Kellner et al, 2002). It is not possible to reproduce in
vitro experiments identically in vivo because no current therapy
protocol for breast cancer consists of a monotherapy with Topo IIa
inhibitors. It would nevertheless be difficult to explain the
predictive superiority of Ki-S7 compared with Ki-67 than by a
higher availability of substrate for the anthracycline component of
the therapy regimen (Kellner et al, 2002). It is true that the
assessment of the immunopositive cell fraction does not allow
conclusions as to the protein content of individual cells, and that a
low expression at the cellular level might account for the failure of
a number of tumours with a high percentage of Ki-S7-positive cells
to respond to therapy. More likely, however, this lack of
responsiveness is attributable to resistance mechanisms (Kellner
et al, 2002) acquired during tumour progression, consistent with a
lower response rate in larger tumours (Gieseler et al, 2003).
On the other hand, we found a high Ki-S7 expression indicative
of an aggressive tumour phenotype in terms of higher SBR grade,
hormonal receptor negativity and p53 overexpression. These
observations substantiate the results of previous studies (Jarvinen
et al, 1996; Rudolph et al, 1999a, b). Since wild-type p53 negatively
regulates the promoter of the human TOP2a gene (Sandri et al,
1996b), the immunohistochemical detection of p53, consistent with
a nonfunctional protein, may be expected to be associated with
high levels of Topo IIa.
Contrary to previous results from our group (Rudolph et al,
1999a) and others (Jarvinen et al, 1996, 1998; Rudolph et al,
1999b), we failed to observe a significant positive correlation
between Topo IIa expression and Her-2/neu-overexpression in this
series. Approximately 50% of the Her-2/neu overexpressing
tumours in our series contained high levels of Topo IIa, whereas
in the remaining 50%, Topo IIa was low (Table 1). This finding is
congruent with the results of a study by Ja ¨rvinen et al (2000). In 97
breast cancers, these authors found no Topo IIa gene copy
aberrations when the Her-2/neu gene status was normal, yet when
Her-2/neu was amplified, TOP2a was coamplifed in 44% and
deleted in 42% of the cases. Such data may explain the contra-
dictory results of different reports analysing breast cancer
susceptibility to Topo IIa inhibitors in relation to the Her-2/neu
status (Muss et al, 1994; Paik et al, 1998; Vincent-Salomon et al,
2000). In the same study, Ja ¨rvinen et al (2000) observed an
increased sensitivity to doxorubicin in a breast cancer cell line
(UACC-812) with TOP2a gene amplification and consequent
protein overexpression and conversely, a decreased sensitivity to
doxorubicin in a breast cancer cell line with TOP2a deletion and
concomitantly reduced protein content (MDA-361). In a previous
study on 863 primary operable invasive ductal carcinomas with
long-term follow-up (Rudolph et al, 1999a), of which only a minor
proportion had been treated with Topo IIa inhibitors, high Topo
IIa expression consequently emerged as an important independent
predictor of adverse outcome next to nodal metastasis and before
other classical or immunohistochemical factors, including Ki-67.
However, no such correlation between Topo IIa and survival was
found in the present series. This could be attributable to a balanced
effect of the Topo IIa expression portending increased chemo-
sensitivity to Topo IIa inhibitors on the one hand and a higher
malignant potential on the other (Kellner et al, 2002).
Primary chemotherapy in breast cancer enhances the rate of
breast conservation and enables the in vivo assessment of tumour
sensitivity to different chemotherapeutic drugs. Clinical decisions
concerning the choice of cytotoxic therapy regimens might be
improved according to the initial tumour response (Wolff and
Davidson, 2000). With this in view, it would be advantageous
to be able to reliably estimate tumour pathologic and biologic
features beforehand in order to tailor the composition of
chemotherapeutic protocols. Mindful of the fact that anthracy-
clines target Topo IIa, we have shown that tumours expressing
high levels of Topo IIa responded better to an anthracycline-based
cytotoxic protocol than tumours with low Topo IIa expression.
Therefore, we conclude that Topo IIa assessment may be of value
for the clinical management of breast cancer in the setting of
primary chemotherapy, provided that our results are corroborated
by further studies.
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